Agoracom Blog Home

Posts Tagged ‘THC’

Enertopia Provides Canadian Medical Marihuana Update

Posted by AGORACOM-JC at 11:00 AM on Friday, June 12th, 2015

  • Signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610
  • Burlington MMPR license application will continue in the application process under new ownership
  • Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program

VANCOUVER, BC / June 12 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces updates with respect to the Burlington and The Green Canvas Joint Ventures.

Enertopia has signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610. The Burlington MMPR license application will continue in the application process under new ownership. The Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program. These monies would be split approximately 50% with Lexaria Corp. Subsequent with this deal the Burlington Joint Venture between Enertopia and Lexaria which was entered into on May 27, 2014 has been terminated due to the pending sale of the project. The Enertopia and Lexaria Master Joint Venture Agreement entered into on March 5, 2014 is still in good standing as both companies continue to look at synergistic opportunities to increase shareholder value.

After thorough examination of the Medical Marihuana industry in Canada and current participants within the sector, it is apparent that raising capital to push projects forward is not currently in the best interests of the Company. Therefore, the Company and The Green Canvas have mutually agreed to terminate their Joint Venture and 6,400,000 shares of Enertopia held in escrow with respect to The Green Canvas Joint Venture will be returned back to corporate treasury and cancelled.

Enertopia is and will continue to be an advocate for medical cannabis for patients and applauds the landmark Supreme Court of Canada ruling on June 11, 2015. This ruling upheld the rights of legal MMAR and MMPR medical cannabis patients in Canada. The unanimous ruling allows valid legal medical patients to choose how they want to administer medical cannabis by the method that is best suited to their medical condition and body absorption. This is looks to be a very positive development for the Canadian medical marihuana sector going forward, as the Federal Government will have to modify or implement a program for the administration of other forms of medical cannabis consumption.

Enertopia will continue to look for opportunities in the MMJ and other sectors that offer the best return for all stakeholders with the least amount of dilution to the Company. The Company looks forward to utilizing its learned knowledge in the MMJ sector and will continue on its path of becoming a licensed producer.

“The Company has completed two milestones in building a stable foundation with its ownership of 1,000,000 shares in Lexaria Corp which has just filed PCT for patent pending bio technologies and the potential of approximately $750,000 in future payments from the Burlington application,” Stated President Robert McAllister

The Company looks forward to providing information via social media, website and press releases as news and events become known over the coming weeks.

About Enertopia

We are a company with the mission to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Company will receive any milestone payments from the sale of Thor Pharma and the Burlington MMPR application, or that the 1,000,000 shares of Lexaria Corp will have any meaningful impact on the Company or the Company will be able to obtain future financings or a license under the MMPR program.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Lexaria Intellectual Property Update

Posted by AGORACOM-JC at 8:24 AM on Friday, May 15th, 2015


KELOWNA, BC / May 15, 2015 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) provides the following update and information regarding its patent-pending technology; how it relates to the delivery of certain active ingredients such as CBD and THC, and how it relates also to market demand.

Lexaria has caused to be filed on April 28, 2015 and May 14, 2015, the latest in a line of provisional patent applications with the United States Patent and Trademark Office regarding its technology that were originally filed beginning in June, 2014. Lexaria’s new patent-pending technology is directed to food and beverage compositions infused with cannabinoids – e.g., THC and/or CBD – that provide enhanced cannabinoid oral bioavailability. We expect the United States Patent and Trademark Office to publish our provisional patent applications roughly in December 2015.

Lexaria’s proprietary process infuses lipids within foods and beverages with cannabinoids and produces compositions with synergistically enhanced cannabinoid absorption and bioavailability. The cannabinoid infused food and beverage compositions have the added benefit of masking the inherent unpleasant taste of cannabinoids to allow for better patient compliance with therapeutically administered cannabinoids.

It is important to understand certain facts:

Smoked or inhaled cannabinoids have reported bioavailabilities ranging from 2-56%, with an average of about 30% (Huestis (2007) Chem. Biodivers. 4:1770-1804; McGilveray (2005) Pain Res. Manag. 10 Suppl. A:15A – 22A). This variability is mainly due to differences in smoking dynamics. Cannabinoids that are absorbed through the mucous membranes in the mouth (buccomucosal application) have bioavailabilities of around 13% (Karschner et al. (2011) Clin. Chem. 57:66-75). By contrast, when cannabinoids are ingested, bioavailability is typically reduced to about 6% (Karschner et al. (2011) Clin. Chem. 57:66-75).

Lexaria’s patent-pending cannabinoid lipid-infusion technology is based in part on the goal of achieving much higher cannabinoid bioavailability than conventional means of oral cannabinoid ingestion.

Oral bioavailability into or approaching the range typical of smoked or inhaled cannabinoids would be potentially disruptive to the entire medical marijuana sector because it would offer patients an efficient option to reduce or even eliminate the need for smoking or inhalation delivery while simultaneously improving conventional edible cannabinoid formats.

To this end, the Company will undertake certain laboratory testing in the coming months to further characterize potentially transformative aspects of the technology and will report the outcome upon completion.

Benefits of the patent-pending technology, include:

1) A positive social health outcome through reduction of smoking of cannabinoids;
2) Improved confidence in consistent delivery of THC or CBD through oral ingestion;
3) Lower cost to consumers relative to conventional edible formats through higher rate of active ingredient delivery;
4) Easy and convenient active ingredient delivery through many readily available common everyday foods;
5) A disruptive competitive advantage for Lexaria versus any company that delivers THC or CBD through any other format, including traditional smoking.

By their nature, new inventions are unpredictable and not always entirely understood in advance. Many complex technologies are being pursued by the broader food and drug industries in relation to more effective delivery of drugs and other ingredients because their traditional oral bioavailability may be poor. Solid lipid nanoparticles, for example, have demonstrated improvements in bioavailability of some Class II, III, and IV drugs as much as 2-25 fold as seen below:

“The US FDA recommended high fat meals for food-effect studies because such fatty meals (800-1000 cal, 50%-65% fat, 25%-30% carbohydrates and 15%-20% proteins) affect GI physiology and maximize drug transfer into the systemic circulation.” (Food and Drug Administration, Guidance for industry: food-effect bioavailability and fed bioequivalence studies, food and drug administration. www.fda.gov)

Maximizing bioavailability is a common aim throughout the food, pharmaceutical and drug industries since efficiencies in delivering active ingredients also deliver many benefits.

About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that patent-pending applications will result in granted patents, or that competing companies, in their normal course of business, might not introduce other unrelated inventions superior to the Company’s own. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Lexaria’s ViPova(TM) Tea Available Soon at Amazon.com

Posted by AGORACOM-JC at 8:32 AM on Wednesday, April 8th, 2015

KELOWNA, BC / ACCESSWIRE / April 8, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is very pleased to announce that ViPova(TM) tea will soon be available for sale at Amazon.com and other online retailers.

“We expect to have ViPova tea available for sale at the world’s largest online superstore,” said Lexaria CEO Chris Bunka. “We know we need to make our products more widely available and we couldn’t be more proud than to start at the top, with the world’s best online retailer.”

Small businesses like ViPova, world-class retail brands, and individual sellers increase their sales and reach new customers by leveraging the power of the Amazon.com e-commerce platform. Amazon.com strives to be Earth’s most customer-centric company and serves consumers through a focus on vast selection, price, and convenience. At peak times, Amazon USA sells as many as 426 items per second, or 36.8 million items in a single day. Some reports have indicated that 80-90 million Americans shop at Amazon.com every month. During 2014, Amazon.com reported full year revenue of approx. $88.9 Billion.

Although not available at Amazon today, Lexaria believes it is important to provide disclosure regarding this important pending development as it would mark a potentially significant new sales channel, and availability at Amazon.com should be imminent. Lexaria continues to open sales channels for its ViPova (TM) brand, making progress consistently as to the number of online locations where consumers can access our premium products. These efforts are ongoing and beginning to be productive.

As well, Lexaria has awarded an initial 6-month Search Engine Optimization (SEO) contract designed to increase the visibility of its online brands and support its online retailers and sellers. This SEO contract has already commenced and is expected to provide steadily improved visibility in the months to come, and will be part of our growing efforts to build brand recognition and interest in our products.

Vipova(TM) encourages other retailers, either online or brick-and-mortar, that wish to carry our ground-breaking products to contact us by email at customerservice@vipova.com for distribution information.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.

Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

Lexaria Updates Operations

Posted by AGORACOM-JC at 8:28 AM on Tuesday, April 7th, 2015

KELOWNA, BC /April 7, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) provides the following updates.

VIPOVA TEA

Lexaria is pleased to announce the manufacturing of delicious ViPova(TM) tea in conventional tea-bags has begun: over 80% of all tea sold in North America is sold within teabags. Simplicity of use should make it easier for consumers to achieve more consistent portions and cannabidiol per serving. Lexaria now has the opportunity to offer our tea in smaller retail packages at lower cost to our customers, offering the potential of broader consumer acceptance and wider market penetration.

For those who want to try our tea for the first time, but are reluctant to purchase the existing larger tin for $99, we will for the first time be able to offer much lower prices for smaller packages. We are currently awaiting delivery of our new packaging options which will be ready for retail sale in either April or May. Although the larger tin still offers the best value per serving, Lexaria expects lower entry-level retail prices to make ViPova(TM) Tea available for enjoyment by everyone.

LEXARIA WEBSITE

The new Lexaria website at lexariaenergy.com is under construction and expected to be operational later this month. The new site is focused primarily on the food sciences sector in which we now operate, and will provide more thorough information regarding our patent-pending infusion technology. The new website will be updated regularly with important sector-specific information, and the Company will provide additional information when the new site is ready to launch.

TEA’S GOT A NEW FIREND…

Lexaria is soon launching a new print ad campaign featuring the slogan, “Tea’s Got a new Friend“, a cheeky and fun ad campaign that is sure to provoke conversation. In limited US circulation to begin, this ad campaign will begin within the next 30 days and is expected to broaden as the year unfolds.

According to the Tea Association of the USA Inc, Americans consumed over 79 billion servings of tea in 2012, its popularity far outstripping any alternative health sector. On any given day, over 150 million Americans consume tea, and 84% of all tea consumed is black tea. Lexaria is confident that its unique and proprietary CBD-infusion process will generate success in this very large market.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns. www.lexarienergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Clinical trials high on list for medical marijuana community

Posted by AGORACOM-JC at 2:42 PM on Tuesday, February 17th, 2015

The medical marijuana movement is asking the scientific community to make examining the therapeutic potential of cannabis in much more depth a priority, cannabis experts from North America and the UK declared on 14 February at the American Association for the Advancement of Science (AAAS) annual meeting in California. But the drug’s controlled status is continuing to slow efforts to investigate the myriad compounds in the plant.

The panellists said the evidence is clear that cannabinoids can treat different types of pain effectively. In addition, they cited some evidence that cannabinoids help with neurological conditions like epilepsy. There is also very early clinical trial data suggesting that the molecule cannabidiol (CBD) has an antipsychotic effect and some evidence that it could help with anxiety disorders.

Although cannabis use is associated with things like short-term memory loss and learning problems, the experts presented data showing that once use is stopped those effects disappear within a few days. They also said there is no proof of any long-term neurocognitive effects of chronic marijuana use on the adult brain, although there is some cause for concern about heavy use by adolescents.

The question of whether the compounds have untoward effects remains unclear due to insufficient research. The field is stalled because large clinical trials require the deep pockets of the pharmaceutical sector, but a major barrier is the lack of intellectual property around some of these compounds. ‘They are old drugs, they are hard to lock in patents, and that makes it difficult for someone to invest significantly into these kinds of research studies that might not have the long-term payback,’ explained Mark Ware, who runs the pain research unit at McGill University, Canada.

However, possession of cannabis is still illegal in most US states making it a difficult drug to work with in the clinic. Igor Grant, a neuropsychiatrist who directs the cannabis research centre at the University of California, San Diego, US, has conducted seven clinical trials that involved smoked or inhaled cannabis and all required that he obtain regulatory approvals from three separate agencies before he could even acquire the cannabis for the studies.

Research marijuana for the US is grown by University of Mississippi under government licence. Once investigators clear all of the approvals, they can request the study drug from the NIH in the form of cigarettes containing different concentrations of tetrahydrocannabinol or THC – the main psychoactive constituent of cannabis.

Cannabis in Canada

Cannabis research is far easier to pursue in Canada where there is a regulated government programme. The country controls cannabis differently to other drugs, arguing that it fits neither under natural health product regulations that govern the use of herbal medicines, nor under the pharmaceutical drug regulations.

Some of the Canadian companies that grow cannabis under licence are now funding clinical trials to try and develop a drug, according to Ware. ‘The money is out there, but the trick is to get these kinds of pilot studies – proof-of-concept studies – done that encourage people to do larger-scale trials,’ he said.

The experts agreed that more information is needed about therapeutic use of cannabis. To help fill this gap, the provincial ethics committee in Quebec recently directed that all patients cleared to use cannabis for medical reasons must agree to be part on an ongoing study. Ware has been tapped to help set up a Quebec-wide registry that will allow these patients to be tracked anonymously for adverse events, as well as for things like pain, spasticity, appetite level and mood. The registry is expected to go live by the end of March.

In the US, there has been much media and public interest in a strain of medical marijuana first developed to treat a child suffering from repeated seizures, dubbed Charlotte’s Web, which is high in CBD but does not contain any psychoactive compounds. But Ware is troubled by the phenomenon of parents and patients seeking out CBD therapeutics. ‘We don’t know where the cannabidiol is coming from; there is a tremendous kind of mythology about the stuff coming from eastern Europe or China,’ he said. Hemp farmers in Canada are being approached to produce CBD and are charging huge amounts of money, he added.

The development of such medicinal products is complicated by the fact that cannabis contains over 100 different ingredients that may be bioactive. This flies in the face of the model followed by regulatory agencies like the US Food and Drug Administration that are set up to deal with single molecules rather than complex mixtures.

Source: http://www.rsc.org/chemistryworld/2015/02/clinical-trials-high-list-medical-marijuana-community

Supreme Completes Operational Transition to Ontario

Posted by AGORACOM-JC at 12:25 PM on Monday, February 9th, 2015

TORONTO, ONTARIO–(Feb. 9, 2015) – Supreme Pharmaceuticals Inc. (the “Company”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce it has completed its operational transition from British Columbia to Ontario in order to focus resources on the Kincardine facility. The transition allows the Company to reduce operating overhead and focus efforts on obtaining required regulatory approvals at the Kincardine facility.

Further to the transition, Brayden Sutton will be resigning as Executive Vice-President, effective immediately, but will continue on with Company as a consultant for the near term to assist in completing the Company’s operational transition.

John Fowler, President of the Company stated, “Re-focusing our attention on Ontario is a big step in our journey to become a leading supplier of affordable medical marijuana in Canada. It allows us to concentrate on building our business around our flagship greenhouse facility. With our focus set squarely on Kincardine, I feel we are well positioned for future success.”

Currently, the Company continues to prepare for its post-license operations by engaging with various health care providers, patient groups and wholesale partners. At present, no date has been set for the pre-license regulatory inspection.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
info@supreme.ca
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Updates Operations

Posted by AGORACOM-JC at 9:45 AM on Wednesday, February 4th, 2015

KELOWNA, BC / February 4, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) provides the following three operational updates.

CREDIT CARDS

Lexaria is pleased to announce it is now accepting Mastercard and Visa credit card payments at its www.vipova.com e-commerce site for sales of its patent-pending CBD-infused black tea across America. Previously, customers could only transact with the ViPova website with checks and money orders, and while these payment options remain for those who prefer them, Vipova’s ability to accept major credit cards will shorten delivery times and provide the ease of ordering that customers expect.

Given the increase in web traffic Vipova.com has experienced, Lexaria believes the ability to use credit cards should lead to an increase in sales volumes. Customers across the US can also call 1-888-976-8482 from 9AM to 7PM EST Mon-Fri to place their orders.

FOCUS GROUPS

Lexaria has begun holding focus group sessions to introduce and evaluate its CBD-infused black tea. Our first focus group was held January 29 when 14 people were introduced to ViPova Tea. The session provided a chance for potential consumers to learn about the tea and the properties of cannabidiol infusion, and proved immensely valuable to the Company to learn about consumer preferences, needs, likes and dislikes.

Lexaria is very pleased at the enthusiastic response and comments received. Participants had the opportunity to meet senior representatives of ViPova, and provide detailed commentary that the Company will use to fine-tune its products and marketing as 2015 unfolds.

The next focus group will be held during the next several days and the Company expects to continue to hold similar focus group meetings in the weeks and months to come.

STRATEGIC ADVISOR

Lexaria has engaged Sequoia Partners Inc for strategic fiscal advisement and for the development of various strategies to assist the Company to realize its project objectives. Lexaria will be working closely with the Managing Partners of Sequoia to pursue its interests. The Managing Partners have extensive and long lasting relationships in the finance, health care and pharmaceutical industries that are expected to be beneficial to the Company.

Sequoia has been granted 250,000 stock options and will receive a monthly fee of CDN$5,000 for the next six months.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexariaenergy.com.

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “could”, “should”, “will”, and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

CLIENT FEATURE: Lexaria (LXX: CSE) Application in Progress to Produce 10,000kg of Med Marijuana Per Year

Posted by AGORACOM-JC at 11:35 AM on Wednesday, January 7th, 2015

(LXX: CSE, LXRP: OTCQB)

Regulated Marijuana Production

  • Burlington joint venture approximately 75,000 sq ft in total potential space
  • Applied to produce 10,000kg of Medical Marijuana per year
  • Planned production areas have 22 foot ceilings which will allow for the possibility of a 2nd mezzanine level in many areas, allowing for additional future expansion.
  • Closed 51% acquisition of Poviva Tea, LLC

Gupta: ‘I am doubling down’ on medical marijuana


Dr. Sanjay Gupta, CNN Cheif Medical Correspondent. We have no affiliation with this well known medical expert, but his latest “Doubling Down” on the medical marijuana sector is worthy of your attention. Reasons such as these convince us we are doing the right thing in entering this market.

Medical marijuana and ‘the entourage effect’

Today, most Americans and most Canadians support some form of medical use of marijuana, in poll after poll.

Likewise, the legal marijuana industry is and will be heavily regulated, and we support that. We’ve already proven our ability to be transparent with our stakeholders and our ability to work within all applicable government regulations. We promise to deliver that transparency and dedication to the legal marijuana industry where these traits are a vital component towards ultimate success.


The medical marijuana business just might be one of the most recession-proof industry sectors there are. There is no boom and bust cycle that is apparent. The average demographic age in North America continues to increase, with over 44 million people in the USA today at the age of 65 or over. Age-related illnesses will continue to grow, and some fraction of these people looking for an alternative to opiate-based painkillers have a real need for pain-relief choices.

12 Month Stock Chart


Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Supreme Appoints John Fowler President & Director

Posted by AGORACOM-JC at 1:47 PM on Friday, December 19th, 2014

VANCOUVER, BRITISH COLUMBIA–(Dec. 19, 2014) - Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (OTC PINK:SPRWF)(CSE:SL) is pleased to report that at its annual meeting today John Fowler was elected to the board of directors and appointed as the President of the Company. The Company has also added Dr. Youbin Zheng to its advisory board.

Mr. John Fowler, previously Director of Operations, was elected to the board of directors, and will be assuming the position of President of Supreme. Mr. Fowler began working in the medical marijuana sector over ten years ago. He pursued a career in law to assist medical marijuana patients with legal issues ancilliary to medical marijuana use. Most recently, Mr. Fowler practiced law at a prominent Toronto law firm. Mr. Fowler is committed to providing Canadians access to high-quality, low-cost medical marijuana and working with the medical community to improve physician education and support for medical marijuana.

Dr. Youbin Zheng, PhD, MPhil, MAg, Bag, has been appointed as the newest member of the Company’s advisory board. Mr. Zheng is currently an Associate Professor and Environmental Horticulture Chair, at the University of Guelph. He has many years of experience in horticulture research, especially in vegetable and ornamental plant production in controlled environments (e.g. greenhouses) in Canada, England, Japan and China. Recent research projects include greenroofs, urban agriculture, organic vegetable production in greenhouses, CO2 enrichment and its effects on photosynthesis, respiration, transpiration, nutrient uptake and crop production, irrigation and water treatment for sustainable horticulture, and the development of sustainable plant production systems. Mr. Zheng is a highly distinguished expert in the field of horticulture and will be a key advisor to the Company and its grow operations moving forward.

The Company has agreed to settle certain payment obligations pursuant to a consulting agreement by the issuance of 390,000 common shares of the Company on January 2, 2015.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
430 – 580 Hornby Street, Vancouver BC, V6C 3B6
604.674.2191
info@supreme.ca
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Mazorro Provides Update on GrowPros MMP Activities

Posted by AGORACOM-JC at 8:36 AM on Wednesday, December 17th, 2014

OTTAWA, ONTARIO–(Dec. 17, 2014) - Mazorro Resources Inc. (the “Company“) (CSE:MZO)(FRANKFURT:JAM) announces that, further to its press release November 6, 2014 announcing the signature of a definitive agreement with GrowPros MMP Inc. (“GrowPros“) and in anticipation of a successful closing of the proposed amalgamation (“Amalgamation“), management of GrowPros has provided the following update on its activities.

GrowPros is finalizing the second revision to its application for a license under the Marihuana for Medical Purposes Regulations (“MMPR“). These revisions are part of the normal review process and GrowPros is impressed by the expediency with which its file has been reviewed by Health Canada. In addition, GrowPros will be closing the previously-announced transaction for the purchase of 190 acres of agricultural land located 45 minutes North of Ottawa, Ontario which will house a 50,000 sq. ft. production facility with unlimited room for expansion. As a result, management of GrowPros advises that it expects to receive a ready to build authorization from Health Canada in the second quarter of 2015.

GrowPros also reports that it is currently in preliminary negotiations with companies in various service and supply segments of the cannabis production industry. Management of GrowPros advises that merging main stream business into the cannabis industry will be a major focus of GrowPros going forward. Accordingly, these opportunities should provide a higher return on investment for GrowPros and, ultimately, a quicker route to profitability than solely being an applicant or licensed MMPR producer. This is in line with GrowPros‘ philosophy as a medical marihuana consultation and acquisition firm.

As previously announced on December 3, 2014, the Company would like to remind shareholders that the special meeting of the Company’s shareholders to approve the (i) proposed change of business from mineral resource exploration to the medical marijuana industry and (ii) change of name to “GrowPros Cannabis Inc. / Entreprise GrowPros cannabis inc.” will be held on December 29, 2014 (the “Special Meeting“). A notice of meeting, management information circular, and form of proxy in respect of the Special Meeting has been sent to shareholders and is available under the Company’s profile on the CSE website and on SEDAR.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to complete the Amalgamation and change of business, failure to obtain sufficient financing, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Any forward-looking statement speaks only as of the date on which it is made and except as may be required by applicable securities laws. The Company disclaims any intent or obligation to update any forward-looking statement.

Mazorro Resources Inc.
André Audet
Interim President, CEO, and CFO
(613) 241-2332